Vanguard Group Inc. Has $912.68 Million Stock Position in Roivant Sciences Ltd. $ROIV

Key Points

• Vanguard raised its Q4 stake in Roivant by 8.4% to 42,059,041 shares — about 6.05% of the company — valued at roughly $912.68 million.
• Insiders have sold 5,085,398 shares worth approximately $139.2 million in the last 90 days, while insiders still own about 10.8% of the stock.
• Analysts give Roivant a consensus "Moderate Buy" rating with an average price target of $30.55, compared with a current share price near $27.83 and a market cap of about $19.9 billion.

Vanguard Group Inc. grew its stake in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 42,059,041 shares of the company's stock after purchasing an additional 3,254,113 shares during the quarter. Vanguard Group Inc. owned about 6.05% of Roivant Sciences worth $912,681,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Jones Financial Companies Lllp lifted its stake in shares of Roivant Sciences by 226.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company's stock valued at $25,000 after purchasing an additional 1,148 shares during the period. Allworth Financial LP raised its stake in Roivant Sciences by 48.1% during the 3rd quarter. Allworth Financial LP now owns 1,795 shares of the company's stock worth $27,000 after buying an additional 583 shares during the period. Bessemer Group Inc. raised its stake in Roivant Sciences by 41.5% during the 3rd quarter. Bessemer Group Inc. now owns 1,852 shares of the company's stock worth $28,000 after buying an additional 543 shares during the period. Farther Finance Advisors LLC raised its stake in Roivant Sciences by 59.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,600 shares of the company's stock worth $78,000 after buying an additional 1,345 shares during the period. Finally, Aster Capital Management DIFC Ltd raised its stake in Roivant Sciences by 75.8% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,405 shares of the company's stock worth $67,000 after buying an additional 1,900 shares during the period. Institutional investors and hedge funds own 64.76% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. HC Wainwright raised their price objective on Roivant Sciences from $33.00 to $34.00 and gave the stock a "buy" rating in a research note on Wednesday, March 4th. Weiss Ratings downgraded Roivant Sciences from a "hold (c-)" rating to a "sell (d)" rating in a research note on Monday, February 9th. Guggenheim raised their price objective on Roivant Sciences from $28.00 to $30.00 and gave the stock a "buy" rating in a research note on Monday, February 9th. TD Cowen reaffirmed a "buy" rating on shares of Roivant Sciences in a research note on Wednesday, March 4th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.55.

Roivant Sciences Trading Down 2.5%

ROIV stock opened at $27.83 on Friday. The stock has a 50-day moving average price of $28.30 and a two-hundred day moving average price of $23.96. The stock has a market cap of $19.92 billion, a PE ratio of -23.79 and a beta of 1.14. Roivant Sciences Ltd. has a 1 year low of $10.58 and a 1 year high of $30.33.

Insider Activity

In other Roivant Sciences news, insider Mayukh Sukhatme sold 339,441 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the completion of the transaction, the insider owned 19,148,664 shares in the company, valued at approximately $506,865,136.08. This represents a 1.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel Allen Gold sold 425,000 shares of the stock in a transaction dated Wednesday, February 11th. The stock was sold at an average price of $26.67, for a total value of $11,334,750.00. Following the transaction, the director owned 15,928,113 shares of the company's stock, valued at approximately $424,802,773.71. This trade represents a 2.60% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 5,085,398 shares of company stock worth $139,215,946. 10.80% of the stock is currently owned by insiders.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.